← All trials
NCT01174030
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2010
- Primary completion
- Dec 1, 2010
- Completion date
- Jan 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 269
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- GaldermaLead sponsor
- Dermatology, Laser & Vein Specialists of the CarolinasOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- GaldermaStudy director
- DermDoxOverall official - principal investigator
- Dermatology Consulting Services, High Point NCOverall official - principal investigator
- Minnesota Clinical Study CenterOverall official - principal investigator
- Meda Phase, Inc.Overall official - principal investigator
- Arlington Center for DermatologyOverall official - principal investigator
- Philadelphia Institute of DermatologyOverall official - principal investigator
- Burke Pharmaceutical ResearchOverall official - principal investigator
- Palmetto Clinical Trial Services, LLCOverall official - principal investigator
- Premier Research GroupOverall official - principal investigator
- Oregon Medical Research CenterOverall official - principal investigator
- Oregon Dermatology and Research CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.